HST GLOBAL, INC. Inactive Instrument
HST Global, Inc. Share Price Other OTC
Equities
HSTC
US40432E2028
Biotechnology & Medical Research
| Sales 2022 | - | Sales 2023 | - | Capitalization | 3.19M 254M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | - |
| Net Debt 2022 | 75.89K 6.05M | Net Debt 2023 | 96.79K 7.71M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.34
x | P/E ratio 2023 |
-21.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 37.71% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Ron Howell
CEO | Chief Executive Officer | 75 | 07/05/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ron Howell
CEO | Chief Executive Officer | 75 | 07/05/08 |
HST Global, Inc. is an integrated health and wellness biotechnology company. The Company is focused on developing and /or acquiring a network of wellness centers worldwide that is primarily focused on the homeopathic and alternative treatment of late-stage cancer. The Company intends to acquire innovative products for the treatment of life-threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late-stage cancer and/or life-threatening diseases. The Company has not generated any revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.77% | 42.86B | |
| +45.26% | 41.36B | |
| +12.24% | 42.74B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
